Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Arozal W., Watanabe K., Veeraveedu P.T., Ma M., Thandavarayan R.A., Sukumaran V., Suzuki K., Kodama M., Aizawa Y.
32067462200;55492737200;12796732500;7202444988;23390800400;35070365600;55624483910;7403312707;36051317800;
Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats
2010
Toxicology
274
1-3
18
26
45
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Department of Pharmacology, Faculty of Medicine, University of Indonesia, Jakarta 10430, Indonesia; Department of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan; First Department of Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
Arozal, W., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan, Department of Pharmacology, Faculty of Medicine, University of Indonesia, Jakarta 10430, Indonesia; Watanabe, K., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Veeraveedu, P.T., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Ma, M., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Thandavarayan, R.A., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Sukumaran, V., Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, 265-1 Higashijima Akiha-ku, Niigata City 956-8603, Japan; Suzuki, K., Department of Gastroenterology and Hepatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan; Kodama, M., First Department of Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan; Aizawa, Y., First Department of Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
Daunorubicin (DNR) is one of the anthracycline anti-tumor agents widely used in the treatment of acute myeloid leukemia. However, the clinical use of DNR has been limited by its undesirable systemic toxicity, especially in the heart and kidney. This study was designed to test the effectiveness of carvedilol, a nonselective β-blocker against DNR-induced cardiotoxicity and nephrotoxicity. Rats were treated with a cumulative dose of 9. mg/kg body weight DNR (i.v.). Carvedilol was administered orally every day for 6 weeks. DNR rats showed cardiac and nephrotoxicities as evidenced by worsening cardiac and kidney functions, which were evaluated by hemodynamic and echocardiographic studies, and by measuring protein in urine, levels of urea and creatinine in serum, lipid profiles, malondialdeyde level and the total level of glutathione peroxidase activity in both heart and kidney tissues. These changes were reversed by treatment with carvedilol, which resulted in significant improvement in the cardio-renal function. Furthermore, carvedilol down-regulated matrix metalloproteinase-2 expression in the heart, increased nephrin expression in the kidney, and attenuated the increased protein expression of NADPH oxidase subunits in heart and kidney. Moreover, carvedilol reduced myocardial and renal apoptosis and improved the histopathological changes in heart and kidney induced by DNR. In conclusion, the present study demonstrated a beneficial effect of carvedilol treatment in the prevention of DNR-induced cardiotoxicity and nephrotoxicity by reversing the oxidative stress and apoptosis. © 2010 Elsevier Ireland Ltd.
Apoptosis; Carvedilol; Daunorubicin; Oxidative stress
carvedilol; caspase 7; creatinine; daunorubicin; gelatinase A; glutathione peroxidase; malonaldehyde; messenger RNA; nephrin; protein bcl 2; reduced nicotinamide adenine dinucleotide phosphate oxidase; tissue inhibitor of metalloproteinase 1; urea; animal experiment; animal model; animal tissue; apoptosis; article; body weight; cardiotoxicity; controlled study; creatinine blood level; down regulation; drug efficacy; echocardiography; enzyme activation; enzyme activity; heart function; heart left ventricle enddiastolic pressure; heart left ventricle pressure; heart muscle injury; heart protection; hemodynamics; histopathology; kidney function; lipid analysis; male; mortality; nephrotoxicity; nick end labeling; nonhuman; priority journal; protein expression; rat; renal protection; reverse tr
0300483X
TXCYA
20452391
Article
Q1